Our Mission: Highlighting Innovations by showcasing breakthroughs in cancer research, including diagnostic tools, therapies, and preventive measures.

Colorectal

Learn about colorectal health, including prevention, screening, and treatment options for colorectal diseases. Stay informed on the latest advancements in colorectal cancer research.

ASTRO

Amarogentin suppresses cell proliferation and EMT process through inducing ferroptosis in colorectal cancer – BMC Gastroenterology

Background Colorectal cancer (CRC) is one common tumor with the high death rate, and badly affects the normal lives of CRC patients. Amarogentin (AG) has been found to exhibit regulatory roles and join into the progression of multiple diseases. However, the regulatory impacts and associated molecular mechanisms of AG in CRC progression keep unclear. Methods and results In this study, it was demonstrated that AG weakened CRC cell viability in a concentration- and time-dependent manner. In addition, AG accelerated cell apoptosis by triggering ferroptosis. The cell invasion and EMT process were restrained after AG treatment, but these impacts were reversed after Fer-1 addition. Moreover, it was uncovered that AG retarded Nrf2/HO-1/GPX4 activation. Additionally, AG modulated PTC cell viability and stimulated ferroptosis. At last, it was illustrated that AG suppressed tumor growth in vivo. Conclusion In conclusion, it was disclosed that AG suppressed cell proliferation and EMT process through inducing ferroptosis in CRC, and retarded Nrf2/HO-1/GPX4 activation. This discovery suggested that AG may be one effective drug for ameliorating CRC progression.

Read More »
MD Anderson

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

Read More »
NEW ATLAS

Cancer protein discovery reveals new treatment target

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not only improves our understanding of why this type of cancer can be aggressive in some people, but it also highlights a potential treatment target.

Read More »
error: Content is protected !!